$264 Million is the total value of Tamarack Advisers, LP's 31 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 325.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DGX | Buy | QUEST DIAGNOSTICS INCequity | $25,455,000 | -1.1% | 317,000 | +29.4% | 9.64% | +63.9% |
| PRGO | New | PERRIGO CO PLCequity | $19,236,000 | – | 400,000 | +100.0% | 7.28% | – |
| UTHR | Buy | UNITED THERAPEUTICS CORPequity | $15,267,000 | +16.6% | 161,000 | +6.3% | 5.78% | +93.3% |
| MYL | Buy | MYLAN NVequity | $13,419,000 | +47.6% | 900,000 | +100.0% | 5.08% | +144.6% |
| NUAN | New | NUANCE COMMUNICATIONS INCequity | $10,488,000 | – | 625,000 | +100.0% | 3.97% | – |
| CHNG | New | CHANGE HEALTHCARE INCequity | $6,993,000 | – | 700,000 | +100.0% | 2.65% | – |
| OPTN | Buy | OPTINOSE INCequity | $6,960,000 | -18.8% | 1,550,000 | +47.6% | 2.64% | +34.6% |
| MRK | New | MERCK & CO. INC.equity | $6,925,000 | – | 90,000 | +100.0% | 2.62% | – |
| New | GLD US 01/15/21 C150call | $4,305,000 | – | 3,500 | +100.0% | 1.63% | – | |
| PGNX | New | PROGENICS PHARMACEUTICALSequity | $4,180,000 | – | 1,100,000 | +100.0% | 1.58% | – |
| BDX | New | BECTON DICKINSON AND COequity | $3,447,000 | – | 15,000 | +100.0% | 1.30% | – |
| PFE | New | PFIZER INCequity | $3,264,000 | – | 100,000 | +100.0% | 1.24% | – |
| SIBN | New | SI-BONE INCequity | $2,474,000 | – | 207,000 | +100.0% | 0.94% | – |
| EW | New | EDWARDS LIFESCIENCES CORPequity | $1,886,000 | – | 10,000 | +100.0% | 0.71% | – |
| MSON | New | MISONIX INCequity | $1,873,000 | – | 198,800 | +100.0% | 0.71% | – |
| EHTH | New | EHEALTH INCequity | $1,408,000 | – | 10,000 | +100.0% | 0.53% | – |
| PODD | New | INSULET CORPequity | $828,000 | – | 5,000 | +100.0% | 0.31% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.